BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18753975)

  • 1. A comparative analysis of lymphatic vessel density in ovarian serous tumors of low malignant potential (borderline tumors) with and without lymph node involvement.
    Fadare O; Orejudos MP; Jain R; Mariappan MR; Hecht JL; Renshaw IL; Hileeto D; Wang SA; Ghofrani M; Liang SX
    Int J Gynecol Pathol; 2008 Oct; 27(4):483-90. PubMed ID: 18753975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors).
    Fadare O
    Int J Gynecol Cancer; 2009 Jan; 19(1):103-8. PubMed ID: 19258950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
    Sangoi AR; McKenney JK; Dadras SS; Longacre TA
    Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases.
    Maniar KP; Wang Y; Visvanathan K; Shih IeM; Kurman RJ
    Am J Surg Pathol; 2014 Jun; 38(6):743-55. PubMed ID: 24441661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors.
    Takeshima N; Hirai Y; Umayahara K; Fujiwara K; Takizawa K; Hasumi K
    Gynecol Oncol; 2005 Nov; 99(2):427-31. PubMed ID: 16112718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2010 Jan; 34(1):1-9. PubMed ID: 19898226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 May; 30(5):614-24. PubMed ID: 16699316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic serous borderline ovarian tumor in an internal mammary lymph node: a case report and review of the literature.
    Chamberlin MD; Eltabbakh GH; Mount SL; Leavitt BJ
    Gynecol Oncol; 2001 Jul; 82(1):212-5. PubMed ID: 11426990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
    Nilforoushan N; Moatamed NA
    Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.
    Seidman JD; Kurman RJ
    Hum Pathol; 2000 May; 31(5):539-57. PubMed ID: 10836293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased intratumoral lymphatic vessel density correlates with lymph node metastasis in early gastric carcinoma.
    Lee K; Park DJ; Choe G; Kim HH; Kim WH; Lee HS
    Ann Surg Oncol; 2010 Jan; 17(1):73-80. PubMed ID: 19777179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma.
    Ma Y; Hou Y; Liu B; Li X; Yang S; Ma J
    Anat Rec (Hoboken); 2010 Nov; 293(11):1847-54. PubMed ID: 20730866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
    Matsuo K; Wong KK; Fotopoulou C; Blake EA; Robertson SE; Pejovic T; Frimer M; Pardeshi V; Hu W; Choi JS; Sun CC; Richmond AM; Marcus JZ; Hilliard MAM; Mostofizadeh S; Mhawech-Fauceglia P; Abdulfatah E; Post MD; Saglam O; Shahzad MMK; Karabakhtsian RG; Ali-Fehmi R; Gabra H; Roman LD; Sood AK; Gershenson DM
    J Surg Oncol; 2018 Feb; 117(2):236-244. PubMed ID: 28787528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
    Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
    Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
    Kennedy AW; Hart WR
    Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lateral peritumoral lymphatic vessel invasion can predict lymph node metastasis in esophageal squamous cell carcinoma.
    Mori D; Yamasaki F; Shibaki M; Tokunaga O
    Mod Pathol; 2007 Jun; 20(6):694-700. PubMed ID: 17464319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses.
    Bakkar R; Gershenson D; Fox P; Vu K; Zenali M; Silva E
    Int J Gynecol Pathol; 2014 May; 33(3):302-8. PubMed ID: 24681743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.